Delivery Order SPE2DB25D3006-SPE2DB25FXJVX
- Not listed
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $38,515.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injections on July 18, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The delivery is scheduled for completion by July 21, 2025, with performance at the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors, with a contract ceiling value of $15,256.35 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a branded GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a $10,414.19 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) under a firm fixed-price contract. The award was made on July 18, 2025, with an ultimate completion date of July 21, 2025, and is being performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order carries no set-aside designation, indicating it was competitively awarded on an open basis. This delivery order is issued...
- The Defense Logistics Agency awarded a $26,993.06 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on July 18, 2025, with completion targeted for July 21, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement executed by the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $23,423.40 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound 12.5 mg/0.5 ml pens valued at $7,543.07 on July 18, 2025, with completion targeted for July 21, 2025. This firm fixed-price delivery order, which received no set-aside designation, will be performed at AmerisourceBergen's Corporate Office facility in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction within the company's existing indefinite delivery vehicle with DLA...
- The Defense Logistics Agency awarded a $6,581.41 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 ml pens on July 18, 2025, with completion targeted for July 21, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $2,697.75 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting AmerisourceBergen's ability to compete successfully in open federal procurement. Performance will be completed by July 21, 2025, with fulfillment occurring at the contractor's facility in Conshohocken, Pennsylvania. This...
- SPE2DB25D3006Indefinite Delivery Contract
- SPE2DB25D3006-SPE2DB25FXJVXDelivery Order
The Defense Logistics Agency has awarded a $13,342.07 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units). The contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a small-value transaction executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This order is a child contract executed under AmerisourceBergen's $999.99 billion prime indefinite delivery vehicle with DLA Troop Support Medical (SPE2DX), which runs through December 2026 and serves as a comprehensive global pharmaceutical support platform for military healthcare systems worldwide. The contract reflects DLA's continued reliance on AmerisourceBergen as a critical pharmaceutical distributor supporting Defense Health Agency requirements and other federal healthcare customers. Zepbound, a semaglutide-based weight-management medication, represents part of the specialized pharmaceutical portfolio that AmerisourceBergen delivers to support military medical operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.3k | 7/18/25 |